Private neural-engineering company developing PRIMA retinal prostheses, biohybrid neural interfaces and related platforms. Founded by Max Hodak, Alan Mardinly and Emma Zhou. Company reported approximately $490M invested as of March 2026.
Founded 2021
Emma Zhou Co-Founder, Director of BCI Research
SHOW MORE
$230M 2026-03-05 Lightspeed , Khosla Ventures , Y Combinator , IQT , Quiet Capital , 885 Capital , Mangusta Capital , Octant Ventures , RRE Ventures , Bayshore Global Management , In-Q-Tel , Lightspeed Venture Partners $— 2025-04-15 Khosla Ventures $103M 2025-04-14 Khosla Ventures , Quiet Capital $25M 2024-06-06 IQT $113M 2022-11-21 Byers Capital , Blake Byers , Juan Benet $47M 2021-07-21 ARTIS , Jed McCaleb $— 2021 Khosla Ventures $— Unknown date Kaleida Capital
SHOW MORE
team@apexlogos.ai · 11 hours ago
BCI research snapshot, reviewed 2026-10-06. Company identity: ScienceCorporation. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts.
Part 2/2
C as separate review fields. Update current leadership roles after review; do not overwrite a former role based on an undated page.
Read-only `Org` lookup found the following records. The snapshot below records existing claims, **not verification of those claims**. SHOW MORE
team@apexlogos.ai · 11 hours ago
BCI research snapshot, reviewed 2026-10-06. Company identity: ScienceCorporation. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts.
Part 1/2
# Science Corporation
Research date: **2026-10-06**. Review material only; no adex data was modified. All linked sources and HTML image references were accessed on this date.
## Identity and operating status
**Science Corporation / Science Corp.**, private clinical-stage neural engineering company founded in **2021**, headquartered in **Alameda, California**, with offices in Research Triangle Park and Paris. [Official company/contact](https://science.xyz/company/ )
Programs include **PRIMA** retinal implant, **Biohybrid** neural interface, **Vessel** perfusion platform and neural engineering/foundry tools. PRIMA is a retinal visual prosthesis: avoid describing every Science product as a cortical recording BCI. [Official technology portfolio](https://science.xyz/technologies/ )
Current news includes 2026-10-05 three-year PRIMA clinical follow-up. The March financing release described pending CE-mark/FDA applications. Later humanitarian-use device designation is not in itself US marketing approval. Verify geography-specific commercial authorization at import rather than turning expected approval into fact. [Official news](https://science.xyz/news/ )
## Audit of pasted BCI.INTEL entry
| Pasted claim | Assessment |
|---|---|
| San Francisco HQ | Correct to Alameda; both are Bay Area, but distinct municipalities. |
| Max Hodak founder/CEO | Confirmed; official leadership also identifies co-founders Alan Mardinly and Emma Zhou. |
| $490M total | Confirmed as approximate company-reported capital invested in 2026-03-05 release. |
| PRIMA / biohybrid interface | Confirmed programs; clinical/research and regulatory stages differ. |
| ACTIVE | Supported by financing, hiring, current scientific and leadership announcements. |
## Company profile image
Direct logo/profile image: [Official square organization logo](https://science.xyz/images/meta/android-chrome-512x512.png ) explicitly exposed as `Organization.logo.url` in official site JSON-LD. Additional [company logo on background](https://science.xyz/_astro/logo-on-background-02.Cn1J7iK8_Z1f2YgA.jpeg ) is the official `og:image` of current appointment releases. Source: [Science company page](https://science.xyz/company/ ).
## Founders and public team
| Person | Role / relationship | Profile and role evidence | Direct profile image URL |
|---|---|---|---|
| Max Hodak | Current: Co-Founder, Chief Executive Officer | [Official profile](https://science.xyz/company/team/max-hodak ) | [PFP (XPRIZE)](https://assets-us-01.kc-usercontent.com:443/9bc15d1f-8a5c-007d-b507-e3496e85af86/38903e09-797d-4035-aa51-89146cb0fcf9/Max%20Hodak.webp ) |
| Darius Shahida | Current: President | [Official profile](https://science.xyz/company/team/darius-shahida ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Alan Mardinly, PhD | Current: Co-Founder, Chief Scientific Officer | [Official profile](https://science.xyz/company/team/alan-mardinly ) | [PFP (personal site)](https://alanmardinly.com/assets/portrait.jpg ) |
| Emma Zhou | Current: Co-Founder, Director of BCI Research | [Official profile](https://science.xyz/company/team/emma-zhou ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Alex Feerst, PhD | Current: Chief Legal Officer | [Official profile](https://science.xyz/company/team/alex-feerst ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Frank Brodie, MD | Current: Chief Medical Officer, Ophthalmology | [Official profile](https://science.xyz/company/team/frank-brodie ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Richard Socarides | Current: Chief Communications Officer | [Official profile](https://science.xyz/company/team/richard-socarides ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Aaron Bartnick | Current: Chief of Staff | [Official profile](https://science.xyz/company/team/aaron-bartnick ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Davin Hsieh | Current: VP of Finance | [Official profile](https://science.xyz/company/team/davin-hsieh ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Joe Mornin | Current: General Counsel | [Official profile](https://science.xyz/company/team/joe-mornin ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Kylie Alsofrom | Current: Executive Vice President of Operations | [Official profile](https://science.xyz/company/team/kylie-alsofrom ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Marcus Simon | Current: Director of Market Access | [Official profile](https://science.xyz/company/team/marcus-simon ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Matthias Wagner | Current: Director of Biohybrid Devices | [Official profile](https://science.xyz/company/team/matthias-wagner ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Murat Günel, MD | Current: Medical Director for BCI | [Official profile](https://science.xyz/company/team/murat-gunel ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Nevada Sanchez | Current: Executive Vice President of Engineering | [Official profile](https://science.xyz/company/team/nevada-sanchez ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Ralf Hornig, PhD | Current: Director of Clinical Affairs | [Official profile](https://science.xyz/company/team/ralf-hornig ) | Unavailable; official personal profile has no headshot in retrieved HTML |
| Stephen Geer | Current: Head of External Affairs | [Official profile](https://science.xyz/company/team/stephen-geer ) | Unavailable; official personal profile has no headshot in retrieved HTML |
Darius Shahida is now **President**, effective announcement September 17, 2026; March financing release called him Chief Strategy Officer. [Promotion announcement](https://science.xyz/news/leadership-shahida/ ) Nevada Sanchez joined as EVP of Engineering in July 2026. [Appointment](https://science.xyz/news/leadership-sanchez/ ) Portrait search covered the full official leadership grid, individual official profiles, appointment releases and personal/institutional biographies. Max’s portrait comes from XPRIZE; Alan’s from his personal site. Unavailable rows must stay empty at import; no random scientist photos substituted.
## Investments and financing
| Date | Type | Amount (USD) | Lead | Named participants | Evidence |
|---|---|---:|---|---|---|
| 2026-03-05 | Series C | $230M | Not identified as lead in company release | Khosla Ventures; Lightspeed Venture Partners; Y Combinator; IQT; Quiet Capital; others unnamed | [Official financing release](https://science.xyz/news/series-c/ ) |
The release explicitly says these are **pre-existing investors** and reports approximately **$490M** invested since 2021. Do not infer their earliest round, individual cheque or an extra $260M single round from that total. SEC CIK is **1873836**, whose [2021 Form D filing index](https://www.sec.gov/Archives/edgar/data/1873836/000187383621000002/0001873836-21-000002-index.htm ) provides a primary path to earlier financing. Secondary histories conflict ($47.32M A, $113M B, later notes/extensions and totals up to $520M); those are not promoted to validated transactions here because amounts sold, offering targets and overlapping amendments need reconciliation. This financing history is therefore incomplete.
**Acquisition distinct from financing:** Science obtained PRIMA assets from Pixium Vision in 2024; do not treat asset purchase price as funding raised. [Official PRIMA program](https://prima.science.xyz/ ) No grant or debt amount is verified in this report. Company total is a reported aggregate, not audited lifetime equity.
### Earlier issuer filing, separate from later Series C
[SEC Form D filed 2021-07-21](https://www.sec.gov/Archives/edgar/data/1873836/000187383621000002/xslFormDX01/primary_doc.xml ) identifies Science Corp., Delaware incorporation in2021, Alameda principal address and first sale2021-07-06. It records **$47,324,986 sold** to14investors against **$49.5M offered**. Record sold proceeds, not the target; round name and investor identities are not established by the filing. Related persons include Max Hodak officer/director and Jed McCaleb director; a director is not automatically a named investor. This early equity offering must not be double-counted with later historical totals.
## Existing adex match and review decision
Already present as `ScienceCorporation`. Existing description correctly uses Alameda. Existing financing evidence contains unverified third-party histories; keep the official $490M total dated and the $230M Series SHOW MORE
team@apexlogos.ai · 22 days ago
COMPETITION 
Alan MardinlyCo-Founder, Chief Scientific Officer
Max HodakCo-Founder, Chief Executive Officer